Clinical trials: Cancer Vaccine
Epithelial Ovarian Cancer
Ovarian Cancer Vaccine for Patients in Remission
The purpose of this study is to determine the safety and efficacy of an investigational therapeutic agent (Cvac) in ovarian cancer patients in first or second remission and to determine its ability to prevent cancer from…
- Trial name
- NCT01068509
- Testing
- Cvac
- Where
- 18 sites in United States, Australia
- Volunteers
- 63 people
- Sponsor
- Prima BioMed Ltd
Hematopoietic Cell Transplantation Recipient, Malignant Neoplasm
High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant
This phase II randomized trial studies how well high dose flu vaccine works in treating children who have undergone done stem cell transplant.
- Conditions
- Hematopoietic Cell Transplantation Recipient, Malignant Neoplasm, Influenza
- Trial name
- NCT02860039
- Testing
- Trivalent Influenza Vaccine, Quadrivalent Influenza Vaccine, Laboratory Biomarker Analysis
- Where
- 9 sites in United States
- Volunteers
- 170 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Infections, Papillomavirus
Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. Indeed, certain oncogenic types of HPV can infect the cervix (part of the uterus or womb).
- Trial name
- NCT00196937
- Testing
- Cervarix
- Where
- 6 sites in Germany, Poland
- Volunteers
- 667 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hormone Refractory Prostate Cancer
RNActive®-Derived Therapeutic Vaccine
This is a Phase I/IIa open, uncontrolled, prospective study, to be conducted in an out-patient setting. The present study is one of two clinical trials of the RNActive®-derived vaccine CV9103 being conducted concurrently in the…
- Trial name
- NCT00906243
- Testing
- CV9103
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Florida
Infections, Papillomavirus
Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study
This extension study is designed to assess the safety of GSK Biological's human papillomavirus (HPV) vaccine GSK580299 in female subjects who took part in the primary study NCT00294047 and received the control vaccine in…
- Trial name
- NCT01190189
- Testing
- GSK580299 (Cervarix)
- Where
- 28 sites in United States, Canada
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Recurrent Glioblastoma, Recurrent Adult Brain Tumor
Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
This randomized phase II trial studies how well giving vaccine therapy with or without bevacizumab works in treating patients with recurrent glioblastoma multiforme that can be removed by surgery.
- Conditions
- Recurrent Glioblastoma, Recurrent Adult Brain Tumor, Gliosarcoma
- Trial name
- NCT01814813
- Testing
- HSPPC-96, bevacizumab
- Where
- 417 sites in United States
- Volunteers
- 90 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Pancreatic Cancer
QUILT-3.080: NANT Pancreatic Cancer Vaccine
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with pancreatic cancer who have progressed on or after previous Standard of Care (SoC) chemotherapy.
- Trial name
- NCT03586869
- Testing
- Aldoxorubicin HCl, ALT-803, ETBX-011
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- ImmunityBio, Inc.
Neoplasms, Rectal
A Post-marketing Surveillance Study to Assess the Safety of Cervarix (GlaxoSmithKline [GSK] Biologicals' Human Papillomavirus [HPV] -16/18 Vaccine), When Administered According to the Approved Prescribing Information (PI) in Korea
The purpose of this post-marketing surveillance (PMS) study is to collect safety information on the use of Cervarix upon the expanded indication to anal cancer to both women and men (at least 600 Korean women and men) within 30…
- Trial name
- NCT03671369
- Testing
- Safety data collection (following routine vaccination) by a continuous surveillance method.
- Where
- 29 sites in South Korea
- Volunteers
- 670 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Glioblastoma Multiforme, Glioblastoma
Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme
The purpose of this research study is to determine if an investigational dendritic cell vaccine, called pp65 DC, is effective for the treatment of a specific type of brain tumor called glioblastoma (GBM) when given with stronger…
- Conditions
- Glioblastoma Multiforme, Glioblastoma, Malignant Glioma, Astrocytoma, Grade IV
- Trial name
- ATTAC-II (NCT02465268)
- Testing
- pp65-shLAMP DC with GM-CSF, unpulsed PBMC and saline, Td
- Where
- 3 sites in United States
- Volunteers
- 175 people
- Sponsor
- University of Florida
Meningococcal Meningitis, Human Papillomavirus Infection
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adolescents
This study will evaluate the safety and immune response of the Novartis Meningococcal ACWY conjugate vaccine when administered with Tdap and HPV vaccinations to healthy adolescents
- Conditions
- Meningococcal Meningitis, Human Papillomavirus Infection, Pertussis, Tetanus
- Trial name
- NCT00518180
- Testing
- Novartis Meningococcal ACWY Conjugate Vaccine, Tdap Vaccine
- Where
- Costa Rica
- Volunteers
- 1,620 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer
This randomized phase II trial studies how well glycosylated recombinant human interleukin-7 (CYT107) after vaccine therapy works in treating patients with castration-resistant prostate cancer that has spread to other areas of…
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer
- Trial name
- NCT01881867
- Testing
- Glycosylated Recombinant Human Interleukin-7, Laboratory Biomarker Analysis
- Where
- 16 sites in United States
- Volunteers
- 54 people
- Sponsor
- Fred Hutchinson Cancer Center
Breast Cancer, Breast Neoplasms
Vaccination of High Risk Breast Cancer Patients - A Combined Phase I/II Feasibility-and-Efficacy Study
The purpose of this study is to evaluate a new investigational cancer vaccine, P10s-PADRE in combination with standard neoadjuvant chemotherapy and surgery in patients with clinical stage I, II or III estrogen-receptor…
- Trial name
- NCT02229084
- Testing
- P10s-PADRE/ MONTANIDE™ ISA 51 VG, Doxorubicin, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 58 people
- Sponsor
- University of Arkansas
HPV-associated Cancer
An Extended Follow-Up Study of the HPV Vaccine Delayed Booster Trial
This is an extended follow-up study to follow-up study participants who received 1 booster dose of Gardasil 9 in the "HPV vaccine delayed booster trial." This was a prospective, single-arm, open-label, non-randomized, phase IIa…
- Trial name
- NCT04688476
- Where
- 2 sites in United States
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- University of Arizona
Cervical Cancer, Vulvar Cancer
Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)
The purpose of this study was to evaluate the safety, efficacy, and immunogenicity of V503 in comparison to GARDASIL. The primary hypotheses tested in the study were 1) V503 administered to 16- to 26-year-old adolescents and…
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, Genital Warts
- Trial name
- NCT00543543
- Testing
- Comparator: GARDASIL, Experimental: V503
- Volunteers
- 14,840 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Infections, Papillomavirus
Human Papillomavirus (HPV) Vaccine (Cervarix TM) Efficacy, Immunogenicity & Safety Trial in Adult Japanese Women With GSK Biologicals HPV-16/18 Vaccine
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. Indeed, certain oncogenic types of HPV can infect the cervix (part of the uterus or womb).
- Trial name
- NCT00316693
- Testing
- HPV-16/18 vaccine (Cervarix™), Aimmugen™
- Where
- 4 sites in Japan
- Volunteers
- 1,046 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Breast Cancer
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
The study will be a multi-center, prospective, randomized, single-blinded, placebo-controlled Phase II trial of Herceptin + NeuVax(TM) vaccine (E75 peptide/granulocyte macrophage-colony stimulating factor) (GM-CSF) versus…
- Trial name
- NCT01570036
- Testing
- Herceptin, NeuVax vaccine, GM-CSF
- Where
- 29 sites in United States
- Volunteers
- 275 people
- Sponsor
- George E. Peoples
Infections, Papillomavirus
Safety Study of GSK Biologicals' HPV Vaccine (GSK-580299) in Healthy Female Subjects.
This study will collect safety data of GlaxoSmithKline Biologicals' human papillomavirus (HPV) vaccine in healthy females of Chinese origin who are unable to receive all three doses of commercially available HPV vaccine before…
- Trial name
- NCT00811798
- Testing
- Cervarix
- Where
- Hong Kong
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infections, Papillomavirus
Evaluation of the Immune and Safety Response of GlaxoSmithKline (GSK) Biologicals' HPV Vaccine in Healthy Indian Women
Human papillomavirus infection has clearly been recognized as the cause of cervical cancer. Indeed, the infection of the cervix by certain oncogenic types of HPV, if not cleared , can lead over time to cervical cancer in women .
- Trial name
- NCT00344032
- Testing
- HPV-16/18 VLP/AS04 Vaccine (Cervarix TM)
- Where
- 4 sites in India
- Volunteers
- 354 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Advanced Non-small Cell Lung Cancer
AST-VAC2 Vaccine in Patients With Non-small Cell Lung Cancer
This clinical study is looking at a vaccine called AST-VAC2 in adult patients with advanced non-small cell lung cancer (NSCLC). The main aim of the study: If the dose can be given safely to patients, learn more about the…
- Trial name
- NCT03371485
- Testing
- AST-VAC2
- Where
- 2 sites in United Kingdom
- Volunteers
- 9 people
- Sponsor
- Cancer Research UK
Male Breast Cancer, Recurrent Breast Cancer
Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer
This randomized phase I/II trial studies the side effects and best dose of vaccine therapy and to see how well it works when given together with 1-methyl-D-tryptophan (1-MT) in treating patients with metastatic breast cancer.
- Conditions
- Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT01042535
- Testing
- adenovirus-p53 transduced dendritic cell (DC) vaccine, 1-methyl-d-tryptophan, Laboratory biomarker analysis
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute